Collaborative rheumatologic–ophthalmologic teams could improve management of patients with rheumatic diseases

News
Article

Austrian investigators recommend an interdisciplinary, rheumatologic–ophthalmologic approach to disease management

A nurse helps a patient who uses a walker and glasses. Image credit: ©Dorde – stock.adobe.com

Authors concluded an interdisciplinary rheumatologic–ophthalmologic setting could further improve the management of patients with rheumatic diseases. Image credit: ©Dorde – stock.adobe.com

Austrian investigators advise establishing an interdisciplinary setting, ie, rheumatologic–ophthalmologic, to improve management of patients with rheumatic diseases.1 The investigators were led by first author Ralf Altenberger, MD, from Clinic II, Department of Internal Medicine, Medical University of Innsbruck, and colleagues from the Department of Ophthalmology and Optometry, Medical University of Innsbruck, Austria.

The investigators pointed out that spondyloarthritis (SpA) and Behçet disease are typical diseases that require the expertise of rheumatologists and ophthalmologists. Uveitis is a recognised extraskeletal manifestation of both SpA2 and Behcet disease.3 However, at least 10 other inflammatory rheumatic diseases are potentially associated with uveitis.4

The authors commented, “Additionally, there are many more ocular manifestations that possibly present with a rheumatic disease, from keratoconjunctivitis sicca in Sjögren syndrome to visual disturbances and even visual loss in giant cell arteritis. Thus, eye involvement in rheumatic diseases may have a dramatic impact on the prognosis and quality of life of patients with rheumatic diseases, whereas other eye diseases may occur independently of rheumatic disease.”

Because there are few data on the prevalence of ocular diseases in patients with rheumatologic diseases, the aims of this study were two-fold: to provide data on the retrospectively assessed prevalence of ophthalmologic diseases in real-world data from a rheumatology outpatient clinic and to consider the role of a multi-disciplinary rheumatology–ophthalmology clinic.

The investigators performed a chart review in this retrospective observational cohort study and reported the following: Of the 1,529 rheumatic outpatients, 26.9% had an ophthalmic diagnosis; whereas from a rheumatologic perspective, inflammatory non-infectious diagnoses dominated at 71.7%. From an ophthalmologic perspective, diagnoses without inflammatory pathophysiologic backgrounds dominated at 54.9%. An inflammatory non-infectious ophthalmologic disease was diagnosed in 24.2% of patients with rheumatoid arthritis and 29.3% of patients with peripheral SpA. Not 1 patient with rheumatoid arthritis was diagnosed with anterior uveitis; however, 16.5% of patients with SpA were diagnosed with anterior uveitis, which was significant (p < 0.001). The prevalence of uveitis was 16.3% in axial and 20.1% in peripheral SpA.

The investigators concluded that an interdisciplinary rheumatologic–ophthalmologic setting appears justified to further improve the management of patients with rheumatic diseases.

References

  1. Altenberger R, Rauchegger T, Haas G, et al. Eye disease in patients with rheumatic diseases: a retrospective observational cohort study. J Clin Med. 2023;12:7510; https://doi.org/10.3390/jcm12247510
  2. Dougados M, Baeten D. Spondyloarthritis. Lancet 2011:377:2127–2137.
  3. Davatchi F, Chams-Davatchi C, Shams H, et al. Behcet’s disease: epidemiology, clinical manifestations, and diagnosis. Expert Rev. Clin. Immunol. 2017;13:57–65.
  4. Petris CK Almony, A. Ophthalmic manifestations of rheumatologic disease: diagnosis and management. MO Med. 2012;109:53–58.
Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.